share_log

NexImmune | 8-K: Current report

NexImmune | 8-K: Current report

NexImmune | 8-K：重大事件
美股sec公告 ·  07/19 16:06
Moomoo AI 已提取核心信息
On July 19, 2024, NexImmune, a biotechnology company, held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting was adjourned without conducting any business to allow the company more time to explore alternative strategies that could maximize the value of its business and assets. The adjourned meeting is rescheduled for August 2, 2024, in a virtual format. Stockholders as of the record date, June 19, 2024, are entitled to vote and need not resubmit their proxy if they have already voted. NexImmune continues to solicit votes for the proposals outlined in the Proxy Statement, which is available on the SEC website. As of June 11, 2024, NexImmune had 1,371,051 shares of common stock and one share of Series A Preferred Stock issued and outstanding. The company's filings with the SEC, including its latest annual report and the definitive Proxy Statement, contain important information about the upcoming Special Meeting and the risks associated with the company's forward-looking statements.
On July 19, 2024, NexImmune, a biotechnology company, held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting was adjourned without conducting any business to allow the company more time to explore alternative strategies that could maximize the value of its business and assets. The adjourned meeting is rescheduled for August 2, 2024, in a virtual format. Stockholders as of the record date, June 19, 2024, are entitled to vote and need not resubmit their proxy if they have already voted. NexImmune continues to solicit votes for the proposals outlined in the Proxy Statement, which is available on the SEC website. As of June 11, 2024, NexImmune had 1,371,051 shares of common stock and one share of Series A Preferred Stock issued and outstanding. The company's filings with the SEC, including its latest annual report and the definitive Proxy Statement, contain important information about the upcoming Special Meeting and the risks associated with the company's forward-looking statements.
2024年7月19日，生物技术公司NexImmune召开了股东特别会议，就公司的清算和解散进行投票。但是，会议未进行任何业务便被暂停，以便公司有更多时间探索可以最大化其业务和资产价值的替代策略。暂停的会议预计于2024年8月2日以虚拟形式重新安排。截至记录日2024年6月19日的股东有权投票，无需重新提交委托书如果他们已经投票。NexImmune继续征求对代理声明中概述的提议的投票，代理声明可在SEC网站上获得。截至2024年6月11日，NexImmune发行并流通的普通股为1,371,051股，A系列优先股为1股。该公司向SEC提交的文件，包括最新的年度报告和明确的代理声明，包含有关即将召开的特别会议和与公司前瞻性声明相关的风险的重要信息。
2024年7月19日，生物技术公司NexImmune召开了股东特别会议，就公司的清算和解散进行投票。但是，会议未进行任何业务便被暂停，以便公司有更多时间探索可以最大化其业务和资产价值的替代策略。暂停的会议预计于2024年8月2日以虚拟形式重新安排。截至记录日2024年6月19日的股东有权投票，无需重新提交委托书如果他们已经投票。NexImmune继续征求对代理声明中概述的提议的投票，代理声明可在SEC网站上获得。截至2024年6月11日，NexImmune发行并流通的普通股为1,371,051股，A系列优先股为1股。该公司向SEC提交的文件，包括最新的年度报告和明确的代理声明，包含有关即将召开的特别会议和与公司前瞻性声明相关的风险的重要信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息